Corot, C., Robert, P., Idee, J. M. & Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58, 1471–1504 (2006).
Daldrup-Link, H. E. et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 17, 5695–5704 (2011).
Klenk, C. et al. Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 15, 275–285 (2014).
Ansari, C. et al. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10, 566–575 (2014).
Neuwelt, E. A. et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60, 601–611 (2007).
Daldrup-Link, H. & Coussens, L. M. MR imaging of tumor-associated macrophages. Oncoimmunology 1, 507–509 (2012).
Vinogradov, S., Warren, G. & Wei, X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine 9, 695–707 (2014).
Miller, M. A. et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun. 6, 8692 (2015).
Weissleder, R., Nahrendorf, M. & Pittet, M. J. Imaging macrophages with nanoparticles. Nat. Mater. 13, 125–138 (2014).
Li, C. A targeted approach to cancer imaging and therapy. Nat. Mater. 13, 110–115 (2014).
Futterer, S., Andrusenko, I., Kolb, U., Hofmeister, W. & Langguth, P. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 86, 151–160 (2013).
Ittrich, H., Peldschus, K., Raabe, N., Kaul, M. & Adam, G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. RoFo 185, 1149–1166 (2013).
Richards, J. M. et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ. Cardiovasc. Imaging 5, 509–517 (2012).
Warheit, D. B. & Hartsky, M. A. Role of alveolar macrophage chemotaxis and phagocytosis in pulmonary clearance responses to inhaled particles: comparisons among rodent species. Microsc. Res. Tech 26, 412–422 (1993).
Sindrilaru, A. et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121, 985–997 (2011).
Wodarz, D. & Anton-Culver, H. Dynamical interactions between multiple cancers. Cell Cycle 4, 764–771 (2005).
Nejadnik, H. et al. Somatic differentiation and MR imaging of magnetically labeled human embryonic stem cells. Cell Transplant. 21, 2555–2567 (2012).
Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364–1377 (2013).
Lu, M., Cohen, M. H., Rieves, D. & Pazdur, R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85, 315–319 (2010).
Choi, J. Y. et al. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 29, 964–970 (2008).
Poljak-Blazi, M. et al. Effect of ferric ions on reactive oxygen species formation, cervical cancer cell lines growth and E6/E7 oncogene expression. Toxicol. In Vitro 25, 160–166 (2011).
Crowe, W. E., Maglova, L. M., Ponka, P. & Russell, J. M. Human cytomegalovirus-induced host cell enlargement is iron dependent. Am. J. Physiol. Cell Physiol. 287, C1023–C1030 (2004).
Petersen, D. R. Alcohol, iron-associated oxidative stress, and cancer. Alcohol 35, 243–249 (2005).
Nie, G., Chen, G., Sheftel, A. D., Pantopoulos, K. & Ponka, P. In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood 108, 2428–2434 (2006).
Knobel, Y., Glei, M., Osswald, K. & Pool-Zobel, B. L. Ferric iron increases ROS formation, modulates cell growth and enhances genotoxic damage by 4-hydroxynonenal in human colon tumor cells. Toxicol. In Vitro 20, 793–800 (2006).
Basel, M. T. et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. Int. J. Nanomedicine 7, 297–306 (2012).
Chung, T. H. et al. Iron oxide nanoparticle-induced epidermal growth factor receptor expression in human stem cells for tumor therapy. ACS Nano 5, 9807–9816 (2011).
Foy, S. P. & Labhasetwar, V. Oh the irony: iron as a cancer cause or cure? Biomaterials 32, 9155–9158 (2011).
Reinisch, W., Staun, M., Bhandari, S. & Munoz, M. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J. Crohns Colitis 7, 429–440 (2013).
Lunov, O. et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 31, 9015–9022 (2010).
Gupta, A. K. & Wells, S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans. Nanobioscience 3, 66–73 (2004).
Mou, W. et al. Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment. Cancer Lett.
358, 115–123 (2015).
Becker, M., Muller, C. B., De Bastiani, M. A. & Klamt, F. The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol. Histopathol. 29, 21–31 (2014).
Laskar, A., Eilertsen, J., Li, W. & Yuan, X. M. SPION primes THP1 derived M2 macrophages towards M1-like macrophages. Biochem. Biophys. Res. Commun. 441, 737–742 (2013).
Solinas, G., Germano, G., Mantovani, A. & Allavena, P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86, 1065–1073 (2009).
Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014).
Edris, B. et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl Acad. Sci. USA 109, 6656–6661 (2012).
Shiao, S. L. et al. TH2-polarized CD4+ T cells and macrophages limit efficacy of radiotherapy. Cancer Immunol. Res. 3, 518–525 (2015).
Hadjipanayis, C. G. et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70, 6303–6312 (2010).
Thorek, D. L. et al. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat. Commun. 5, 3097 (2014).
Rosner, M. H. & Auerbach, M. Ferumoxytol for the treatment of iron deficiency. Expert Rev. Hematol. 4, 399–406 (2011).
Cheng, K. et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun. 5, 4880 (2014).